Researchers Developed a Novel Tool for Proteome-Wide Identification of Small-Molecule Degrader Targets

Small-Molecule Degraders: Targeted Protein Degradation Mechanism and Types

Targeted protein degradation (TPD) is transforming drug discovery by enabling the elimination of specific proteins, expanding treatment possibilities, especially for previously undruggable targets. Unlike traditional inhibitors, small-molecule degraders exploit the cell’s ubiquitin-proteasome pathway to direct target proteins for degradation. There are two primary classes:

1. Proteolysis Targeting Chimeras (PROTACs): Dual-function molecules that link two distinct binding sites—one for the target protein and one for an E3 ubiquitin ligase—via a flexible linker.
2. Molecular Glues: Smaller than PROTACs, these enhance the interaction between the E3 ligase and target protein, promoting ubiquitination and degradation.

Both classes operate catalytically, allowing lower doses and potentially reducing dosing frequency. They can neutralize both enzymatic and scaffolding roles of their targets, offering a comprehensive therapeutic impact.

DegMS: A Groundbreaking Method for Degradome Analysis

While TPD holds tremendous potential, distinguishing direct targets of degraders from secondary proteomic responses is challenging. This is especially true when degraders target transcriptional or translational regulators, triggering broad cellular changes. DegMS addresses this by focusing exclusively on drug-induced degradation without interference from secondary effects. Key aspects of DegMS include:

1. Pulse labeling with azidohomoalanine (AHA) and SILAC amino acids to label a distinct protein pool.
2. Selective drug treatment post-labeling, tracking the pre-labeled proteins alone.
3. AHA-based click chemistry enrichment followed by mass spectrometry for detailed analysis.

This setup allows DegMS to focus solely on degradation events, fully isolating them from any effects on protein synthesis or other downstream cellular responses.

Utility of DegMS in Analyzing Small-Molecule Degraders

DegMS has shown remarkable efficacy in studying known molecular glue degraders, such as dCeMM2 and dCeMM4, which target cyclin K and associated transcriptional regulators CDK12 and CDK13. Unlike traditional proteomic or transcriptomic approaches, DegMS accurately captures the immediate degradation of these proteins.

Furthermore, DegMS successfully identified GSPT1 as the primary target of the degrader CC–885, overcoming challenges posed by GSPT1’s broad role in cellular homeostasis that generally confound other proteomic methods. DegMS isolates the direct degradation of GSPT1, clarifying substrate identification and minimizing off-target effects.

DegMS in Characterizing Uncharacterized Degraders

DegMS is ideal for exploring novel degraders. Applied to an uncharacterized immunomodulatory imide drug (IMiD)-based degrader, DegMS confirmed degradation of IMiD-specific targets, including IKZF1, IKZF3, and ZFP91, while also identifying a novel target, FIZ1, a zinc-finger protein involved in FLT3 signaling. This highlights DegMS’s potential for discovering previously unrecognized substrates, potentially leading to new therapeutic agents aimed at complex proteins typically considered undruggable due to non-catalytic functions.

Applications of DegMS in Drug Discovery and Development

1. Selective Target Identification: Efficiently identifies primary degrader targets while filtering out secondary proteomic effects.
2. Degradation Kinetics Analysis: Allows detailed tracking of degradation kinetics over hours.
3. Known and Novel Target Identification: Effective for both established degraders (e.g., dCeMM2, dCeMM4, CC-885) and uncharacterized ones.
4. Distinguishing Direct vs. Indirect Effects: Separates direct degradation effects from secondary transcriptional/translational changes.
5. Profiling Regulators of Proteome Homeostasis: Useful for degraders targeting proteins with widespread proteome effects, such as transcriptional regulators.
6. Evaluating Drug Specificity: Assesses degrader specificity, crucial for clinical trial compounds.
7. Potential for Broader TPD Research: Suggested applications include autophagy-targeting chimeras (AUTACs) and lysosome-targeting chimeras (LYTACs).
8. Studying Protein Stability: Could study protein stability in autophagy and lysosomal processes.
9. Potential for Protein Stabilization Detection: May also track drug-induced protein stabilization.
10. Identifying E3 Ligase Substrates: Helps identify natural substrates of E3 ligases, valuable for drug discovery.

Conclusion

DegMS represents a substantial advancement in targeted protein degradation research, providing a proteome-wide, degradation-specific analysis method that excludes interference from secondary cellular processes. It enables precise mapping of degradation substrates, facilitating a clearer understanding of both established and novel degraders. With its accuracy and specificity, DegMS holds promise for broad therapeutic applications, offering a powerful tool to discover and optimize drug targets for complex and resistant diseases.

Reference

Degradome analysis to identify direct protein substrates of small-molecule degraders. 

Full article: https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(24)00442-2

Related Articles/Blogs

1. PROTACs: Future Trends and Innovative Drug Development 
2. Advancing PROTAC Therapeutics: Potency Assays for FDA Compliance – Marin Biologic Laboratories
3. Proteolysis-Targeting Vaccines (PROTAVs): A Novel Approach in Cancer Immunotherapy – Marin Biologic Laboratories
4. Cutting-Edge PROTACs: Ready to Transform Clinical Oncology – Marin Biologic Laboratories
5. Expanding the Toolbox of PROTAC Degraders with Covalent Ligands for Genetically Validated Targets – Marin Biologic Laboratories